Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Interest Expense
Cost of servicing the company's debt during the period.
Edesa Biotech, Inc.NASDAQ: EDSA
Interest Expense · Q2 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q2 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.
Context
- Interest expense increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
Interest Expense vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 interest expense of $0 is the highest of the 2 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding EDSA) | $0 | -100.0% | — | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Gross Profit | (118.79K) | (118.19K) | (183.47K) | (186.05K) | (119.27K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M |
| Selling, General & Admin | 5.73M | 5.04M | 4.43M | 4.13M | 4.24M |
| Operating Expenses | 23.68M | 18.37M | 9.22M | 7.01M | 7.79M |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| EBITDA | (13.22M) | (17.43M) | (8.19M) | (5.98M) | (7.07M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.68M) | (18.37M) | (9.22M) | (7.01M) | (7.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 11.17K | 64 | 289.85K | 153.5K | 2.56K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 10.34M | 822.67K | 849.14K | 845.5K | 726.84K |
| Income Before Tax | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.18M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 800 | 800 | 800 | 800 | 800 |
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.74) | (8.37) | (2.93) | (1.93) | (1.27) |
| EPS (Diluted) | (7.73) | (8.37) | (2.93) | (1.93) | (1.27) |
| Weighted Avg Shares | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
| Weighted Avg Shares (Diluted) | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.